ALKAL2
ALK and LTK ligand 2
Also known as: ALKL2_HUMAN, AUGA, FAM150B
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6UX46
- Gene
- ALKAL2
- Ensembl
- ENSG00000189292
- Chromosome
- 2
- Canonical length
- 152 aa
- Protein class
- Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Enables protein tyrosine kinase activator activity and signaling receptor binding activity. Involved in cell surface receptor protein tyrosine kinase signaling pathway; positive regulation of MAPK cascade; and positive regulation of neuron projection development. Is active in extracellular space. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
152 residues, UniProt reviewed canonical sequence.
>Q6UX46|ALKAL2
1 MRGPGHPLLL GLLLVLGAAG RGRGGAEPRE PADGQALLRL VVELVQELRK HHSAEHKGLQ
61 LLGRDCALGR AEAAGLGPSP EQRVEIVPRD LRMKDKFLKH LTGPLYFSPK CSKHFHRLYH
121 NTRDCTIPAY YKRCARLLTR LAVSPVCMED KQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ALKAL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.54
- Highest tissue expression
- 212 nTPM
Expression across tissuesHPA
Tissue
- adrenal gland: 212 nTPM
- ovary: 73 nTPM
- pancreas: 63 nTPM
- blood vessel: 44 nTPM
- lung: 34 nTPM
- testis: 33 nTPM
Single-cell type
- pancreatic duct cells: 212 nCPM
- adrenal cortex cells: 150 nCPM
- cholangiocytes: 143 nCPM
- late primary spermatocytes: 110 nCPM
- late spermatids: 100 nCPM
- early spermatids: 88 nCPM
Immune cell
- memory B-cell: 0.2 nTPM
- naive CD4 T-cell: 0.2 nTPM
- T-reg: 0.2 nTPM
- intermediate monocyte: 0.1 nTPM
- MAIT T-cell: 0.1 nTPM
- memory CD4 T-cell: 0.1 nTPM
Brain region
- basal ganglia: 16 nTPM
- hypothalamus: 14 nTPM
- thalamus: 13 nTPM
- choroid plexus: 13 nTPM
- white matter: 12 nTPM
- amygdala: 12 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.27
- gnomAD pLI
- 0.03
- DepMap mean gene effect
- 0.17
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell surface receptor protein tyrosine kinase signaling pathway
- positive regulation of ERK1 and ERK2 cascade
- positive regulation of ERK5 cascade
- positive regulation of neuron projection development
Molecular functions
- cytokine activity
- receptor signaling protein tyrosine kinase activator activity
- receptor tyrosine kinase binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ALKAL2 as an antibody target. Whether an autoantibody or antibody against ALKAL2 could matter depends on whether native ALKAL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ALKAL2 is annotated at the cell surface, where native ALKAL2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ALKAL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...